Literature DB >> 17487175

High-throughput screening of small molecules for bioactivity and target identification in Caenorhabditis elegans.

Andrew R Burns1, Trevor C Y Kwok, Al Howard, Ed Houston, Karl Johanson, Anthony Chan, Sean R Cutler, Peter McCourt, Peter J Roy.   

Abstract

This protocol describes a procedure for screening small molecules for bioactivity and a genetic approach to target identification using the nematode Caenorhabditis elegans as a model system. Libraries of small molecules are screened in 24-well plates that contain a solid agar substrate. On top of the agar mixture, one small-molecule species is deposited into each well, along with worm food (E. coli), and two third-stage or fourth-stage larval worms using a COPAS (Complex Object Parametric Analyzer and Sorter) Biosort. Three to five days later the plates are screened for phenotype. Images of the wells are acquired and archived using a HiDI 2100 automated imaging system (Elegenics). Up to 2,400 chemicals can be screened per week. To identify the predicted protein target of a bioactive molecule, wild-type worms are mutagenized using ethylmethanesulfonate (EMS). Progeny are screened for individuals resistant to the molecules effects. The candidate mutant target that confers resistance is then identified. Target identification might take months.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17487175     DOI: 10.1038/nprot.2006.283

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   13.491


  42 in total

1.  Evaluation of the toxicity of 2-aminoimidazole antibiofilm agents using both cellular and model organism systems.

Authors:  Sean D Stowe; Ashley T Tucker; Richele Thompson; Amanda Piper; Justin J Richards; Steven A Rogers; Laura D Mathies; Christian Melander; John Cavanagh
Journal:  Drug Chem Toxicol       Date:  2012-01-31       Impact factor: 3.356

2.  Healthspan Pharmacology.

Authors:  Mahtab Jafari
Journal:  Rejuvenation Res       Date:  2015-11-10       Impact factor: 4.663

Review 3.  From genes to function: the C. elegans genetic toolbox.

Authors:  Thomas Boulin; Oliver Hobert
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2011-11-28       Impact factor: 5.814

4.  High-throughput screening for novel anti-infectives using a C. elegans pathogenesis model.

Authors:  Annie L Conery; Jonah Larkins-Ford; Frederick M Ausubel; Natalia V Kirienko
Journal:  Curr Protoc Chem Biol       Date:  2014-03-14

Review 5.  Neurobiological applications of small molecule screening.

Authors:  Andras Bauer; Brent Stockwell
Journal:  Chem Rev       Date:  2008-05-01       Impact factor: 60.622

6.  Using C. elegans for antimicrobial drug discovery.

Authors:  Athanasios Desalermos; Maged Muhammed; Justin Glavis-Bloom; Eleftherios Mylonakis
Journal:  Expert Opin Drug Discov       Date:  2011-06-01       Impact factor: 6.098

7.  Accurate MALDI-TOF/TOF sequencing of one-bead-one-compound peptide libraries with application to the identification of multiligand protein affinity agents using in situ click chemistry screening.

Authors:  Su Seong Lee; Jaehong Lim; Sylvia Tan; Junhoe Cha; Shi Yun Yeo; Heather D Agnew; James R Heath
Journal:  Anal Chem       Date:  2010-01-15       Impact factor: 6.986

8.  Characterizing the transcriptional regulation of let-721, a Caenorhabditis elegans homolog of human electron flavoprotein dehydrogenase.

Authors:  Derek S Chew; Allan K Mah; David L Baillie
Journal:  Mol Genet Genomics       Date:  2009-09-23       Impact factor: 3.291

9.  What have worm models told us about the mechanisms of neuronal dysfunction in human neurodegenerative diseases?

Authors:  Dawn Teschendorf; Christopher D Link
Journal:  Mol Neurodegener       Date:  2009-09-28       Impact factor: 14.195

10.  Selection of inhibitor-resistant viral potassium channels identifies a selectivity filter site that affects barium and amantadine block.

Authors:  Franck C Chatelain; Sabrina Gazzarrini; Yuichiro Fujiwara; Cristina Arrigoni; Courtney Domigan; Giuseppina Ferrara; Carlos Pantoja; Gerhard Thiel; Anna Moroni; Daniel L Minor
Journal:  PLoS One       Date:  2009-10-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.